NEBIVOLOL ROLE IN THE CORRECTION OF INTRACARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURE

Aim. To assess the effectiveness and safety of a super-selective vasodilating β-adrenoblocker (β-AB) nebivolol in patients with NYHA Functional Class (FC) I–III chronic heart failure (CHF), as a complication of coronary heart disease (CHD). Material and methods. In total, 42 patients with post-infar...

Full description

Saved in:
Bibliographic Details
Main Authors: R. L. Dzhanaeva, Z. T. Astakhova, V. Yu. Makoeva
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2012-02-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/1193
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849688689902354432
author R. L. Dzhanaeva
Z. T. Astakhova
V. Yu. Makoeva
author_facet R. L. Dzhanaeva
Z. T. Astakhova
V. Yu. Makoeva
author_sort R. L. Dzhanaeva
collection DOAJ
description Aim. To assess the effectiveness and safety of a super-selective vasodilating β-adrenoblocker (β-AB) nebivolol in patients with NYHA Functional Class (FC) I–III chronic heart failure (CHF), as a complication of coronary heart disease (CHD). Material and methods. In total, 42 patients with post-infarction cardiosclerosis and FC I–III CHF (30 men and 12 women), aged 52–73 years, were examined. Nebivolol was administered once daily, in the morning, as a part of complex CHD treatment, for 12 weeks. The clinical effectiveness of the therapy and its effects on intracardiac hemodynamics (echocardiography) were assessed. Results. After 12 weeks of the treatment, clinical manifestations of CHF decompensation (oedema, dyspnoea, palpitation, and fatigue) were reduced, the mean CHF FC significantly decreased from 3,12±0,08 to 1,88±0,05 (p<0,05), and exercise capacity increased. A significant reduction in systolic and diastolic blood pressure levels was observed among hypertensive patients. In all participants, mean heart rate was significantly reduced, from 76,80±10,41 to 62,0±5,54 bpm (p≤0,05). Nebivolol also improved the parameters of pathological cardiac remodelling and intracardiac hemodynamics. Mean end-diastolic and end-systolic volume decreased by 19,5% and 15,7%, respectively, while mean left ventricular (LV) myocardial mass decreased by 22,4%. Improved systolic function manifested in significantly increased LV ejection fraction (by 23,8%) and fractional shortening (by 38,3%). Nebivolol also improved LV diastolic function, as demonstrated by increased Ve and F/A ratio (from 1,12±0,34 to 1,29±0,45; p<0,05). Conclusion. Nebivolol therapy improved clinical status and extra- and intracardiac hemodynamics in patients with CHF.
format Article
id doaj-art-e3551549459a435c8b6703d110e259aa
institution DOAJ
issn 1560-4071
2618-7620
language Russian
publishDate 2012-02-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj-art-e3551549459a435c8b6703d110e259aa2025-08-20T03:21:54Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202012-02-01014815996NEBIVOLOL ROLE IN THE CORRECTION OF INTRACARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURER. L. Dzhanaeva0Z. T. Astakhova1V. Yu. Makoeva2ОУ ВПО «Северо-Осетинская государственная медицинская академия Росздрава», Владикавказ, РоссияNorth Ossetia State Medical Academy, Vladikavkaz, RussiaNorth Ossetia State Medical Academy, Vladikavkaz, RussiaAim. To assess the effectiveness and safety of a super-selective vasodilating β-adrenoblocker (β-AB) nebivolol in patients with NYHA Functional Class (FC) I–III chronic heart failure (CHF), as a complication of coronary heart disease (CHD). Material and methods. In total, 42 patients with post-infarction cardiosclerosis and FC I–III CHF (30 men and 12 women), aged 52–73 years, were examined. Nebivolol was administered once daily, in the morning, as a part of complex CHD treatment, for 12 weeks. The clinical effectiveness of the therapy and its effects on intracardiac hemodynamics (echocardiography) were assessed. Results. After 12 weeks of the treatment, clinical manifestations of CHF decompensation (oedema, dyspnoea, palpitation, and fatigue) were reduced, the mean CHF FC significantly decreased from 3,12±0,08 to 1,88±0,05 (p<0,05), and exercise capacity increased. A significant reduction in systolic and diastolic blood pressure levels was observed among hypertensive patients. In all participants, mean heart rate was significantly reduced, from 76,80±10,41 to 62,0±5,54 bpm (p≤0,05). Nebivolol also improved the parameters of pathological cardiac remodelling and intracardiac hemodynamics. Mean end-diastolic and end-systolic volume decreased by 19,5% and 15,7%, respectively, while mean left ventricular (LV) myocardial mass decreased by 22,4%. Improved systolic function manifested in significantly increased LV ejection fraction (by 23,8%) and fractional shortening (by 38,3%). Nebivolol also improved LV diastolic function, as demonstrated by increased Ve and F/A ratio (from 1,12±0,34 to 1,29±0,45; p<0,05). Conclusion. Nebivolol therapy improved clinical status and extra- and intracardiac hemodynamics in patients with CHF.https://russjcardiol.elpub.ru/jour/article/view/1193nebivololchronic heart failureintracardiac hemodynamicsdiastolic function
spellingShingle R. L. Dzhanaeva
Z. T. Astakhova
V. Yu. Makoeva
NEBIVOLOL ROLE IN THE CORRECTION OF INTRACARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURE
Российский кардиологический журнал
nebivolol
chronic heart failure
intracardiac hemodynamics
diastolic function
title NEBIVOLOL ROLE IN THE CORRECTION OF INTRACARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURE
title_full NEBIVOLOL ROLE IN THE CORRECTION OF INTRACARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURE
title_fullStr NEBIVOLOL ROLE IN THE CORRECTION OF INTRACARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURE
title_full_unstemmed NEBIVOLOL ROLE IN THE CORRECTION OF INTRACARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURE
title_short NEBIVOLOL ROLE IN THE CORRECTION OF INTRACARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURE
title_sort nebivolol role in the correction of intracardiac hemodynamics in patients with chronic heart failure
topic nebivolol
chronic heart failure
intracardiac hemodynamics
diastolic function
url https://russjcardiol.elpub.ru/jour/article/view/1193
work_keys_str_mv AT rldzhanaeva nebivololroleinthecorrectionofintracardiachemodynamicsinpatientswithchronicheartfailure
AT ztastakhova nebivololroleinthecorrectionofintracardiachemodynamicsinpatientswithchronicheartfailure
AT vyumakoeva nebivololroleinthecorrectionofintracardiachemodynamicsinpatientswithchronicheartfailure